A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Tazarotene/ulobetasol (Primary) ; Tazarotene/ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bausch Health Companies
Most Recent Events
- 25 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 25 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 25 Mar 2022 Planned End Date changed from 1 Jul 2022 to 1 Jun 2023.